# Patient Square Capital LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1819257. Source: https://holderbook.com/funds/1819257-patient-square-capital-lp/

- Reported value: $645.5M
- Positions: 23
- Weight of the ten largest: 80.1%
- Filed: 2026-08-12

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| ROIVANT SCIENCES LTD | [ROIV](https://holderbook.com/stocks/ROIV/) | $283.9M | 8,020,928 | 44.0% | 15 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $51.7M | 276,000 | 8.0% | 1 |
| MIRUM PHARMACEUTICALS INC | [MIRM](https://holderbook.com/stocks/MIRM/) | $30.5M | 260,500 | 4.7% | 7 |
| ABIVAX SA | [ABVX](https://holderbook.com/stocks/ABVX/) | $27.5M | 206,500 | 4.3% | 4 |
| BEONE MEDICINES LTD | [ONC](https://holderbook.com/stocks/ONC/) | $25.7M | 90,020 | 4.0% | 3 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $23.2M | 671,209 | 3.6% | 8 |
| ARGENX SE | [ARGX](https://holderbook.com/stocks/ARGX/) | $21.3M | 23,000 | 3.3% | 5 |
| UNITED THERAPEUTICS CORP DEL | [UTHR](https://holderbook.com/stocks/UTHR/) | $20.1M | 37,120 | 3.1% | 1 |
| BELITE BIO INC | [BLTE](https://holderbook.com/stocks/BLTE/) | $16.9M | 110,000 | 2.6% | 2 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $16.4M | 425,000 | 2.5% | 3 |
| DBV TECHNOLOGIES S A | [DBVT](https://holderbook.com/stocks/DBVT/) | $14.9M | 909,474 | 2.3% | 3 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $13.3M | 220,000 | 2.1% | 3 |
| BIONTECH SE | [BNTX](https://holderbook.com/stocks/BNTX/) | $12.5M | 134,429 | 1.9% | 1 |
| ARCUS BIOSCIENCES INC | [RCUS](https://holderbook.com/stocks/RCUS/) | $11.0M | 355,800 | 1.7% | 3 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $10.8M | 212,500 | 1.7% | 8 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $10.5M | 108,000 | 1.6% | 4 |
| ALLOGENE THERAPEUTICS INC | [ALLO](https://holderbook.com/stocks/ALLO/) | $10.5M | 5,050,000 | 1.6% | 7 |
| EYEPOINT INC | [EYPT](https://holderbook.com/stocks/EYPT/) | $10.3M | 720,000 | 1.6% | 8 |
| ARCUTIS BIOTHERAPEUTICS INC | [ARQT](https://holderbook.com/stocks/ARQT/) | $9.7M | 370,000 | 1.5% | 3 |
| C4 THERAPEUTICS INC | [CCCC](https://holderbook.com/stocks/CCCC/) | $7.5M | 1,608,815 | 1.2% | 1 |
| INVENTIVA SA | [IVA](https://holderbook.com/stocks/IVA/) | $7.4M | 1,967,171 | 1.2% | 1 |
| KYMERA THERAPEUTICS INC | [KYMR](https://holderbook.com/stocks/KYMR/) | $5.4M | 47,500 | 0.8% | 6 |
| FAETH THERAPEUTICS INC | [FTH](https://holderbook.com/stocks/FTH/) | $4.4M | 175,050 | 0.7% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +16.8% | +14.8% | +2.0% | 100% |
| Q1 2026 | +14.6% | -4.6% | +19.2% | 100% |
| Q4 2025 | +36.1% | +2.4% | +33.7% | 100% |
| Q3 2025 | +34.2% | +7.8% | +26.4% | 100% |
| Q2 2025 | +13.7% | +10.5% | +3.3% | 100% |
| Q1 2025 | -10.8% | -4.6% | -6.3% | 100% |
| Q4 2024 | +3.1% | +2.1% | +1.0% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $645.5M | 23 |
| Q1 2026 | $563.6M | 29 |
| Q4 2025 | $467.1M | 28 |
| Q3 2025 | $373.9M | 24 |
| Q2 2025 | $277.4M | 19 |
| Q1 2025 | $241.7M | 19 |
| Q4 2024 | $267.4M | 20 |
| Q3 2024 | $269.4M | 11 |
| Q2 2024 | $215.4M | 2 |
| Q1 2024 | $234.8M | 2 |
| Q4 2023 | $182.9M | 2 |
| Q3 2023 | $182.0M | 2 |